Patents by Inventor Karin Ute JOOSS
Karin Ute JOOSS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220323558Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.Type: ApplicationFiled: May 13, 2021Publication date: October 13, 2022Applicant: Pfizer Inc.Inventors: Joseph John Binder, Paul Jason Cockle, Derek John Falconer, Siradanahalli Guru, Karin Ute Jooss, Marianne Marcela Andrea Martinic, Kenneth Nelson Wills, Helen Kim Cho
-
Publication number: 20220249657Abstract: The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.Type: ApplicationFiled: April 20, 2022Publication date: August 11, 2022Applicant: RINAT NEUROSCIENCE CORP.Inventors: Yasmina Noubia Abdiche, Helen Kim Cho, Wei-Hsien Ho, Karin Ute Jooss, Arvind Rajpal, Sawsan Youssef
-
Patent number: 11338035Abstract: The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.Type: GrantFiled: April 13, 2020Date of Patent: May 24, 2022Assignee: RINAT NEUROSCIENCE CORP.Inventors: Yasmina Noubia Abdiche, Helen Kim Cho, Wei-Hsien Ho, Karin Ute Jooss, Arvind Rajpal, Sawsan Youssef
-
Patent number: 11110158Abstract: The present disclosure provides (a) isolated immunogenic PAA polypeptides; (b) isolated nucleic acid molecules encoding immunogenic PAA polypeptides; (c) vaccine compositions comprising an immunogenic PAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic PAA polypeptide; (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions; and (e) vaccine-based immunotherapy regimens which involve co-administration of a vaccine in combination with an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer.Type: GrantFiled: August 8, 2018Date of Patent: September 7, 2021Assignee: Pfizer Inc.Inventors: Joseph John Binder, Helen Kim Cho, Michael Robert Dermyer, Karin Ute Jooss, Brian Gregory Pierce, Joyce Tsi Tan, Van To Tsai, James Richard Merson
-
Patent number: 11058753Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.Type: GrantFiled: January 18, 2019Date of Patent: July 13, 2021Assignee: Pfizer Inc.Inventors: Joseph John Binder, Paul Jason Cockle, Derek John Falconer, Siradanahalli Guru, Karin Ute Jooss, Marianne Marcela Andrea Martinic, Kenneth Nelson Wills, Helen Kim Cho
-
Publication number: 20200368349Abstract: The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.Type: ApplicationFiled: April 13, 2020Publication date: November 26, 2020Applicant: RINAT NEUROSCIENCE CORP.Inventors: Yasmina Noubia Abdiche, Helen Kim Cho, Wei-Hsien Ho, Karin Ute Jooss, Arvind Rajpal, Sawsan Youssef
-
Patent number: 10660953Abstract: The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.Type: GrantFiled: November 12, 2018Date of Patent: May 26, 2020Assignee: RINAT NEUROSCIENCE CORP.Inventors: Yasmina Noubia Abdiche, Helen Kim Cho, Weihsien Ho, Karin Ute Jooss, Arvind Rajpal, Sawsan Youssef
-
Publication number: 20190142918Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.Type: ApplicationFiled: January 18, 2019Publication date: May 16, 2019Inventors: Joseph John Binder, Paul Jason Cockle, Derek John Falconer, Siradanahalli Guru, Karin Ute Jooss, Marianne Marcela Andrea Martinic, Kenneth Nelson Wills, Helen Kim Cho
-
Patent number: 10251944Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.Type: GrantFiled: January 17, 2017Date of Patent: April 9, 2019Assignee: Pfizer Inc.Inventors: Joseph John Binder, Paul Jason Cockle, Derek John Falconer, Siradanahalli Guru, Karin Ute Jooss, Marianne Marcela Andrea Martinic, Kenneth Nelson Wills, Helen Kim Cho
-
Publication number: 20190038728Abstract: The present disclosure provides (a) isolated immunogenic PAA polypeptides; (b) isolated nucleic acid molecules encoding immunogenic PAA polypeptides; (c) vaccine compositions comprising an immunogenic PAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic PAA polypeptide; (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions; and (e) vaccine-based immunotherapy regimens which involve co-administration of a vaccine in combination with an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer.Type: ApplicationFiled: August 8, 2018Publication date: February 7, 2019Inventors: Joseph John Binder, Helen Kim Cho, Michael Robert Dermyer, Karin Ute Jooss, Brian Gregory Pierce, Joyce Tsi Tan, Van To Tsai, James Richard Merson
-
Publication number: 20170202938Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.Type: ApplicationFiled: January 17, 2017Publication date: July 20, 2017Inventors: Joseph John Binder, Paul Jason Cockle, Derek John Falconer, Siradanahalli Guru, Karin Ute Jooss, Marianne Marcela Andrea Martinic, Kenneth Nelson Wills, Helen Kim Cho
-
Publication number: 20160375115Abstract: The present disclosure provides (a) isolated immunogenic PAA polypeptides; (b) isolated nucleic acid molecules encoding immunogenic PAA polypeptides; (c) vaccine compositions comprising an immunogenic PAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic PAA polypeptide; (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions; and (e) vaccine-based immunotherapy regimens which involve co-administration of a vaccine in combination with an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer.Type: ApplicationFiled: July 11, 2016Publication date: December 29, 2016Inventors: Joseph John BINDER, Helen Kim CHO, Michael Robert DERMYER, Karin Ute JOOSS, Brian Gregory PIERCE, Joyce Tsi TAN, Van To TSAI
-
Patent number: 9468672Abstract: The present disclosure provides (a) isolated immunogenic PAA polypeptides; (b) isolated nucleic acid molecules encoding immunogenic PAA polypeptides; (c) vaccine compositions comprising an immunogenic PAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic PAA polypeptide; (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions; and (e) vaccine-based immunotherapy regimens which involve co-administration of a vaccine in combination with an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer.Type: GrantFiled: March 13, 2015Date of Patent: October 18, 2016Assignee: Pfizer Inc.Inventors: Joseph John Binder, Helen Kim Cho, Michael Robert Dermyer, Karin Ute Jooss, Brian Gregory Pierce, Joyce Tsi Tan, Van To Tsai
-
Publication number: 20150246106Abstract: The present disclosure provides (a) isolated immunogenic PAA polypeptides; (b) isolated nucleic acid molecules encoding immunogenic PAA polypeptides; (c) vaccine compositions comprising an immunogenic PAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic PAA polypeptide; (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions; and (e) vaccine-based immunotherapy regimens which involve co-administration of a vaccine in combination with an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer.Type: ApplicationFiled: March 13, 2015Publication date: September 3, 2015Inventors: Joseph John Binder, Helen Kim Cho, Michael Robert Dermyer, Karin Ute Jooss, Brian Gregory Pierce, Joyce Tsi Tan, Van To Tsai
-
Patent number: 9066898Abstract: The present disclosure provides (a) isolated immunogenic PAA polypeptides; (b) isolated nucleic acid molecules encoding immunogenic PAA polypeptides; (c) vaccine compositions comprising an immunogenic PAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic PAA polypeptide; (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions; and (e) vaccine-based immunotherapy regimens which involve co-administration of a vaccine in combination with an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer.Type: GrantFiled: May 1, 2013Date of Patent: June 30, 2015Assignee: Pfizer Inc.Inventors: Joseph John Binder, Helen Kim Cho, Michael Robert Dermyer, Karin Ute Jooss, Brian Gregory Pierce, Joyce Tsi Tan, Van To Tsai
-
Publication number: 20130295110Abstract: The present disclosure provides (a) isolated immunogenic PAA polypeptides; (b) isolated nucleic acid molecules encoding immunogenic PAA polypeptides; (c) vaccine compositions comprising an immunogenic PAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic PAA polypeptide; (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions; and (e) vaccine-based immunotherapy regimens which involve co-administration of a vaccine in combination with an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer.Type: ApplicationFiled: May 1, 2013Publication date: November 7, 2013Applicant: PFIZER INCInventors: Joseph John BINDER, Helen Kim CHO, Michael Robert DERMYER, Karin Ute JOOSS, Brian Gregory PIERCE, Joyce Tsi TAN, Van To TSAI